Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Johnson & Johnson (

Thousands in UK take legal action against Johnson & Johnson over alleged talc cancer link

High court claim says company knowingly sold product containing asbestos and ‘concealed’ risk to public

The Guardian - UK

The Real Reason Johnson & Johnson Switched to Corn Starch — Too Late to Save Its Reputation?

Johnson & Johnson's belated shift from talc to corn starch in its baby powders came amid mounting litigation—but can it repair the damage to its reputation?

International Business Times UK

Johnson & Johnson, Kenvue Named In First Ever UK Legal Action Over Talc Cancer Claims

Thousands of claimants in the U.K. are suing Johnson Johnson (NYSE:JNJ), accusing the healthcare giant of knowingly selling asbestos-contaminated talcum powder that allegedly caused cancer in consumers. The case, involving roughly 3,000 individuals, is one of the largest product liability claims of its kind to reach the High Court in…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Johnson & Johnson Reportedly Faces Major UK Lawsuit Over Baby Powder Cancer Risks

A legal claim involving 3,000 people has been reportedly filed against Johnson Johnson (NYSE:JNJ) in the U.K., alleging that the company knowingly sold asbestos-contaminated baby powder.

Benzinga

Johnson & Johnson faces UK lawsuit over cancer claims

IN FULL

The Independent UK

Thousands sue Johnson & Johnson in UK over baby powder cancer claims

The pharmaceutical company has been accused of ‘concealing’ the risk to the public for decades

The Independent UK

These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earnings

Johnson Johnson (NYSE:JNJ) on Tuesday reported better-than-expected third-quarter earnings on Tuesday.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst

On Tuesday, Johnson Johnson (NYSE:JNJ) reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75.

Benzinga

Johnson & Johnson Stock Can Keep Rising as Strategy Pays Off

Johnson & Johnson (NYSE: JNJ) beat Q3 estimates, raised revenue guidance, and plans an orthopedics spin-off—analysts see up to 50% upside for JNJ stock.

MarketBeat

Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook

Johnson Johnson (NYSE:JNJ) on Tuesday reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75.

Benzinga

Goldman Sachs, JPMorgan Chase And 3 Stocks To Watch Heading Into Tuesday

With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:

Benzinga

Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch

Health care giant Johnson Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter financial results are reported before market open Tuesday.

Benzinga

FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy

The Food and Drug Administration (FDA) has updated safety labeling for Johnson Johnson's (NYSE:JNJ) Carvykti after receiving reports of immune effector cell-associated enterocolitis (IEC-EC)—a rare but serious complication seen in both clinical trials and postmarketing data.

Benzinga

Trade Tensions, Market Volatility and Other Key Things to Watch this Week

Markets enter a critical week following Friday's dramatic selloff triggered by President Trump's threat of "massive tariffs" against China over tighter rare-earth export rules.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

5 Dividend Kings For Generations Of Passive Income

These are five Dividend Kings, companies with 50+ years of dividend increases, covering recent developments, dividend safety, and valuation, so you can identify candidates for durable income that fit your goals.

Benzinga

Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report

Johnson Johnson (NYSE:JNJ) is reportedly in discussions to acquire Protagonist Therapeutics (NASDAQ:PTGX).

Benzinga

Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Johnson Johnson (NYSE:JNJ) will release earnings results for the third quarter, before the opening bell on Tuesday, Oct. 14.

We Got This Covered

$966 million fine: Johnson & Johnson held accountable for health risks tied to its baby powder

She trusted their baby powder for 80 years. It killed her.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

FDA Expands Johnson & Johnson Ulcerative Colitis Drug Approval To Pediatric Patients

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson Johnson’s (NYSE:JNJ) Simponi (golimumab) for children with moderately to severely active ulcerative colitis (UC) who weigh at least 15 kg.

MarketBeat

Why AbbVie and Johnson & Johnson Could Outperform Pfizer

Pfizer stock is moving higher after being named part of the TrumpRx platform; but two other biopharma companies may offer better long-term growth potential

Benzinga

Options Corner: Despite Political Woes, Kenvue Can Still Make Tylenol Great Again

Amid a contentious political environment, consumer pharmaceutical firm Kenvue Inc (NYSE:KVUE) finds itself under a harsh spotlight. Specifically, its popular drug Tylenol has attracted the ire of the White House. Late last month, President Donald Trump stated on Truth Social that pregnant women shouldn't use Tylenol unless absolutely necessary. With…

MarketBeat

Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants

Trump’s drug price plan drove a Pfizer rally, leaves Eli Lilly buffered by U.S. investments, and could boost JNJ if it secures similar tariff relief.

Benzinga

Coinbase To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

This Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

We Got This Covered

After badmouthing Tylenol, Trump makes deal with their rival company Pfizer

Weird how one happens before the other.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.